Alexa B Kimball, Gregor B E Jemec, Christopher J Sayed, Joslyn S Kirby, Errol Prens, John R Ingram, Amit Garg, Alice B Gottlieb, Jacek C Szepietowski, Falk G Bechara, Evangelos J Giamarellos-Bourboulis, Hideki Fujita, Robert Rolleri, Paulatsya Joshi, Pratiksha Dokhe, Edward Muller, Luke Peterson, Cynthia Madden, Muhammad Bari, Christos C Zouboulis
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
Lancet (London, England)
every medical decision based balancing medical knowledge ethical considerations patient preferences previous surveys mainly covered ethical knowledge medical staff aim study evaluate feasibility innovative concept regarding ethical criteria applied clinical decisionmaking critical illness online survey including short case vignette carried university hospital among physicians specialising intensive care medicine germany free text responses regarding required case information participants asked rank decision criteria course case vignette qualitative evaluation performed two independent investigators based transcription categories followed quantitative analysis ranked criteria analysis shown doctors initially inclined consider medical information making treatment decisions complications occur ethical values often included decisionmaking qualitative evaluation reveiled patients consistently regarded leading criterion decisionmaking quantitative evaluation patients wellbeing quality life patient autonomy rated important decision criteria economic factors ranked least important mixed methods approach able reflect complexity ethical reasoning within medical decisionmaking process suggesting feasibility concept study registered drksid dkrs00011905 april 2017